MiMedx Q1 net sales $59M (-33% YoY), loss $11M; cuts FY guidance to $260-290M

MIMEDX GROUP, INC.

2026-Q1 EPS reported -$0.07 revenue$58,991,000

Q1 net sales $59M, down 33% YoY from $88M; net loss $11M vs net income $7M a year ago.
Surgical product sales up 13% YoY; Wound sales down 60% due to Medicare payment cap per cm².
Gross margin fell to 71% from 81% on pricing pressure and unfavorable product mix.
FY2026 net sales guidance lowered to $260-290M; Adjusted EBITDA expected approximately breakeven.
Company plans $40M annualized cost savings; CEO targets return to profitability in H2 and double-digit growth in 2027.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

MIMEDX GROUP, INC. reported first quarter 2026 results: revenue $59 million, net income $11 million. Guidance lowered.

Period: first quarter 2026
Revenue: $59 million
Net income: $11 million
Guidance: lowered
Result: reported results

Exact text from the filing

MIMEDX Announces First Quarter 2026 Operating & Financial Results Reports First Quarter Net Sales of $59 Million Revises 2026 Net Sales and Adjusted EBITDA Expectations

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

MIMEDX GROUP, INC. filing history →

Source: SEC EDGAR

accession 0001376339-26-000032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.